Recent Developments in Health Law: FDA and Drug Safety: New Tufts Study Challenges Critics of the Prescription Drug User Fee Act

See generally, In re Vioxx Products Liability Litigation 360 F.Supp.2d 1352 (Jud. Pan.Mult.Lit., 2005); In re Paxil Products Liability Litigation 296 F.Supp.2d 1374 (Jud.Pan.Mult.Lit., 2003).

US General Accounting Office (GAO), Food and Drug Administration: Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities, Publication GAO-02-958 (2002), at 1–3, 18.

Prescription Drug User Fee Act of 1992, Pub L No. 102-571, 21 USC §379, 106 Stat 4491 (1992).

Woodcock J. , Drug Safety and the Drug Approval Process, testimony before the Committee on Health, Education, Labor and Pensions, United States Senate, Washington, D.C., March 3, 2005, United States Department Health & Human Services website, at <www.hhs.gov/asl/testify/t050303b.html> (last visited January 5, 2006).

Berndt E. R. , PDUFA, Drug Approval Times, Drug Safety Withdrawal Rates, and the Drug Development Process: Empirical Findings, presentation at FDA Public Meeting: Prescription Drug User Fee Act Public Meeting, National Institutes of Health, Bethesda, MD, November 14, 2005, at <http://www.fda.gov/cber/summaries/pdufa111405eb.pdf> (last visited January 5, 2006).

See GAO, supra note 2, at 3.

PDUFA III Five-Year Plan, at <http://www.fda.gov/oc/pdufa3/2003plan/default.htm> (last visited January 5, 2006).

Berndt E. R. , “Industry Funding of the FDA: Effects of PDUFA on Approval Times and Withdrawal Rates,” Nature Reviews Drug Discovery 4 (2005): 545–554.

Thompson L. , “User Fees for Faster Drug Reviews: Are they Helping or Hurting the Public Health?” FDA Consumer Magazine 34, no. 5 (2000): 25–29, at 26.

See Berndt , supra note 8.

Carpenter D. P. , “The Political Economy of FDA Drug Review: Processing, Politics, and Lessons for Policy,” Health Affairs 23 (2004): 52–63, at 55–56.

Fontanarosa P. B. , “Postmarketing Surveillance-Lack of Vigilance, Lack of Trust,” JAMA 292 (2004): 2647–2650 at 2647.

Pear R. , “Drug Companies Increase Spending to Lobby Congress and Governments,” New York Times, May 31, 2003, at 33.

Beardsley S. , “Avoiding Another Vioxx,” Scientific American 292, no. 2 (2005): 16–17.

See GAO, supra note 2, at 25.

Carpenter D. , “Data Watch: Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter?” Health Affairs (December 17, 2003): W3-618-24, at W3–623.

See Carpenter , supra note 16, at WS-620.

See Carpenter , supra note 16, at WS-623.

Kaitin K. I. , ed., “Drug Safety Withdrawals in the U.S. Not Linked to Speed of FDA Approval,” Tufts Center for the Study of Drug Development Impact Report 7, no. 5 (2005).

See Kaitan , supra note 19.

See Berndt , supra note 5.

Langel S. , “Interest Groups Skeptical of FDA's Risk-Based Assessment System,” Washington Drug Letter 37, no. 40 (2005).

See Langel , supra note 22.

See Langel , supra note 22.

Report to the Nation: Improving Public Health Through Human Drugs, Center for Drug Evaluation and Research, US Department of Health and Human Services (2003): at 39.

Agovino T. , “Vioxx Patient's Death Cost Family $402K,” Business Week Online, December 2, 2005, at <http://www.businessweek.com/ap/financialnews/D8E8F7M85.htm> (last visited December 19, 2005).